Search This Blog

Wednesday, September 20, 2023

Lixte Starts Ovarian Cancer Trial

The Phase 1b Clinical Trial Focuses on Assessing the Safety and Efficacy of the Two-Drug Combination in a Cancer Associated with Longer Survival to Immunotherapy When Genetically Deficient in PP2A

https://finance.yahoo.com/news/lixte-biotechnology-announces-supported-collaborative-123000264.html

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.